IP Library Granted Patent US 11,840,592
Granted Patent B2
US 11,840,592 · App. 17/671,128 · Granted Dec 12, 2023

Preparations of meta-iodobenzylguanidine and precursors thereof

Inventors: Jason Moss (New York, NY); Machinani Rao (New York, NY)
Assignee: Molecular Insight Pharmaceuticals, Inc.
C08F230/04A61K51/0406C07C279/06A61K31/155A61P35/00C07C277/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,840,592
App. No.
17/671,128
Granted
Dec 12, 2023
Kind
B2
Abstract

The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) or a pharmaceutically acceptable salt thereof, the preparation comprising leachable tin at a level of 0 ppm to 850 ppm.

Claims (24)

1. A purified composition of a polymer comprising an acetic acid salt of a monomer of formula (I):

produced by a method comprising the steps of:

counter ion exchange of a hydrochloric acid form of the monomer of formula (I) with sodium acetate to thereby provide a preparation comprising the monomer of formula (I) in the form of an acetic acid salt;

a first solvent treating step, comprising contacting the preparation with aqueous alcohol, and then removing substantially all of the aqueous alcohol;

a second solvent treating step, comprising contacting the preparation with anhydrous alcohol, and then removing substantially all of the anhydrous alcohol so that a solvent-depleted material comprising the polymer is generated; and

subjecting the solvent-depleted material to vacuum, and to a temperature within a range of about 30° C. to about 50° C., the subjecting being performed under conditions and for a time sufficient to thereby provide the purified composition of the polymer, or pharmaceutically acceptable salt thereof;

wherein no more than 150 ppm of leachable tin is present in the purified composition of the polymer.

2. The composition of claim 1 , wherein the aqueous alcohol comprises ethanol.

3. The composition of claim 1 , wherein the anhydrous alcohol is or comprises ethanol.

4. The composition of claim 1 , wherein the aqueous alcohol is or comprises ethanol and the anhydrous alcohol is or comprises ethanol.

5. The composition of claim 1 , the purified composition comprising less than 1.5 wt % water relative to the wt % of the composition.

6. The composition of claim 1 , the purified composition comprising less than 1.0 wt % water relative to the wt % of the composition.

7. The composition of claim 1 , further comprising a step of:

storing the purified composition under an inert gas.

8. The composition of claim 1 , wherein the purified composition comprises less than 2.0 wt % water relative to the wt % of the purified composition.

9. The composition of claim 3 , wherein the first solvent treating step comprises treating the preparation with aqueous ethanol.

10. The composition of claim 9 , wherein the second solvent treating step comprises treating the preparation with absolute ethanol.

11. The composition of claim 1 , wherein the removal of substantially all of the aqueous alcohol or the anhydrous alcohol comprises a first removal step of drying the preparation at ambient temperature and pressure with a flow of nitrogen.

12. The composition of claim 11 , wherein the removal of substantially all of the aqueous alcohol or the anhydrous alcohol comprises a first removal step of drying the preparation at ambient temperature and pressure with a flow of nitrogen and then further comprises a second removal step of drying the preparation at ambient temperature under vacuum with a flow of nitrogen.

13. The composition of claim 1 , wherein the purified composition comprises not more than about 120 ppm of leachable tin.

14. The composition of claim 1 , wherein the purified composition comprises not more than about 90 ppm of leachable tin.

15. The composition of claim 1 , wherein the purified composition comprises not more than about 50 ppm of leachable tin.

16. The composition of claim 1 , wherein the subjecting is performed under conditions and for a time sufficient so that not more than about 0.5 wt % organic solvent relative to the wt % of the composition is present.

17. The composition of claim 1 , wherein the subjecting is performed under conditions and for a time sufficient so that not more than about 0.3 wt % organic solvent relative to the wt % of the composition is present.

Assignments (1)
SECURITY INTEREST Recorded Dec 17, 2025
From: LANTHEUS MEDICAL IMAGING, INC.; PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A., AS COLLATERAL AGENT, NATIONAL BANKING ASSOCIATION
Reel/Frame 073250/0201 →